Bristol-Myers Squibb Co
BMYHealthcare|Drug Manufacturers - General|USA
$58.23
-1.10 (-1.85%)
DCF (FCF)
$68.81
Earnings Power
$30.07
Clinical Trials (564)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06112743 A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | P4 | Active | 63 | Open-label | Mavacamten |
| NCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Hepatocellular Carcinoma, Liver Cancer | P3 | Active | 545 | RCT, Double-blind | Nivolumab |
| NCT02632409 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer | Various Advanced Cancer | P3 | Active | 709 | RCT, Double-blind | Nivolumab |
| NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | Carcinoma, Non-Small-Cell Lung | P3 | Active | 190 | RCT, Open-label | Repotrectinib, Crizotinib |
| NCT03661320 A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer | Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer | P3 | Active | 855 | RCT, Open-label | Nivolumab, Gemcitabine, Cisplatin |
| NCT03141177 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | P3 | Active | 701 | RCT, Open-label | Nivolumab, Cabozantinib, Sunitinib, Ipilimumab |
| NCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | Metastatic Colorectal Cancer | P3 | Active | 839 | RCT, Open-label | Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab |
| NCT03036098 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | Urothelial Cancer | P3 | Active | 1,314 | RCT, Open-label | Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin |
| NCT07011732 A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Alzheimer Disease | P3 | Recruiting | 352 | RCT, Double-blind | Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo |
| NCT07424404 A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively | Schizophrenia, Autism-Related Irritability | P3 | Recruiting | 400 | Open-label | KarXT |
| NCT05980949 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Psychosis Associated With Alzheimer's Disease | P3 | Recruiting | 800 | Open-label | KarXT |
| NCT04934475 MInimal Residual Disease Adapted Strategy | Multiple Myeloma | P3 | Active | 791 | RCT, Open-label | Isatuximab |
| NCT04909801 A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate | Rheumatoid Arthritis | P3 | Active | 338 | RCT, Single-blind | Abatacept, Adalimumab, Methotrexate |
| NCT05469737 A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndromes | P2P3 | Active | 230 | RCT, Double-blind | Oral Azacitidine, Placebo for Oral Azacitidine |
| NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Relapsed or Refractory Multiple Myeloma | P3 | Active | 606 | RCT, Open-label | Mezigdomide, Carfilzomib, Dexamethasone |
| NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Psoriasis | P3 | Active | 1,466 | Open-label | BMS-986165, Placebo |
| NCT07106762 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Urothelial Cancer | P2P3 | Recruiting | 470 | RCT, Open-label | Iza-bren, Cisplatin, Gemcitabine, Carboplatin |
| NCT06253221 A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | P3 | Active | 44 | RCT, Double-blind | Mavacamten, Placebo |
| NCT06976216 A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Alzheimer's Disease | P3 | Recruiting | 586 | RCT, Double-blind | KarXT, KarX-EC |
| NCT04877288 A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications | Renal Allograft Recipients | P3 | Recruiting | 102 | RCT, Open-label | Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids |
| NCT05662241 A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | IgG4 Related Disease | P3 | Active | 194 | RCT, Double-blind | Obexelimab |
| NCT06937229 A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Alzheimer Disease, Agitation | P3 | Recruiting | 600 | Open-label | KarXT, KarX-EC |
| NCT04495296 A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | P1P2 | Recruiting | 320 | Open-label | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab |
| NCT04396821 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer, Gastric Cancer | P1P2 | Active | 150 | Open-label | TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel |
| NCT07297212 A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | P2 | Recruiting | 75 | RCT, Open-label | Pumitamig, Bevacizumab, Temozolomide |
| NCT07255404 A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC) | P2 | Recruiting | 105 | RCT, Open-label | Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX |
| NCT03465592 Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Sarcoma, Solid Tumor, Adult | P1P2 | Recruiting | 39 | Open-label | Nivolumab |
| NCT03607890 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | P2 | Active | 38 | Open-label | Nivolumab, Relatlimab, Nivolumab, Relatlimab, Nivolumab, Relatlimab |
| NCT03815890 Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | Breast Cancer | P2 | Recruiting | 80 | Open-label | Nivolumab, Ipilimumab, Ipilimumab |
| NCT03924401 Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant | Graft Versus Host Disease | P2 | Active | 30 | Open-label | Abatacept |
| NCT05215470 CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | Renal Cancer Metastatic | P2 | Active | 100 | Open-label | Nivolumab, Ipilimumab |
| NCT05197426 A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | Acute Myeloid Leukemia | P2 | Active | 19 | RCT, Double-blind | Oral Azacitidine |
| NCT05732961 Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | Myelodysplastic Syndromes, Myeloproliferative Neoplasm | P2 | Recruiting | 70 | Open-label | Luspatercept |
| NCT06747845 Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | Pancreatic Adenocarcinoma Metastatic | P2 | Recruiting | 68 | RCT, Open-label | Niraparib, FOLFIRI, Ipilimumab |
| NCT03610711 REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | Gastroesophageal Cancer, Immune Checkpoint Inhibition | P1P2 | Active | 21 | Single-blind | Nivolumab, Relatlimab |
| NCT03563248 Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | Pancreatic Cancer | P2 | Active | 168 | RCT, Open-label | FOLFIRINOX, Losartan, Nivolumab |
| NCT05407441 Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors | P1P2 | Recruiting | 49 | Open-label | Tazemetostat, Nivolumab, Ipilimumab |
| NCT06107738 Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma | Multiple Myeloma | P2 | Recruiting | 60 | Open-label | Iberdomide, Daratumumab/rHuPH20 Co-formulation |
| NCT03637543 Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | Prostate Cancer | P2 | Active | 31 | Open-label | Nivolumab |
| NCT05219435 Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | Urothelial Cancer | P2 | Active | 66 | Open-label | Nivolumab, Ipilimumab |
| NCT04446650 A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Primary Myelofibrosis | P1P2 | Active | 31 | Open-label | Fedratinib |
| NCT03650894 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | Breast Neoplasm Female, Breast Cancer | P2 | Active | 30 | Open-label | Nivolumab, Ipilimumab, Bicalutamide |
| NCT04204837 Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | Squamous Cell Carcinoma of the Skin | P2 | Recruiting | 61 | Open-label | Nivolumab, Nivolumab plus Relatlimab |
| NCT04702880 A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer | P2 | Active | 120 | RCT, Open-label | BMS-986012, Carboplatin, Etoposide, Nivolumab |
| NCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Recruiting | 260 | RCT, Open-label | CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone |
| NCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Recruiting | 230 | Open-label | Arlocabtagene Autoleucel |
| NCT05664737 A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | Anemia | P2 | Recruiting | 189 | RCT, Double-blind | Luspatercept, Placebo |
| NCT05492123 Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | Uterine Cervical Neoplasms | P2 | Recruiting | 112 | RCT, Open-label | Nivolumab 40 mg in 4 ml Injection, Ipilimumab 200 MG in 40 ML Injection |
| NCT06015724 Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer | P2 | Recruiting | 54 | Open-label | Daratumumab, KRAS vaccine, Nivolumab |
| NCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure | P2 | Recruiting | 208 | RCT, Double-blind | BMS-986435 |
| NCT03355560 Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy | Head and Neck Cancer | P2 | Active | 39 | Open-label | Nivolumab |
| NCT04933903 BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | Non Small Cell Lung Cancer | P2 | Recruiting | 25 | Open-label | Ipilimumab, Nivolumab |
| NCT02451982 Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | Pancreatic Cancer | P2 | Active | 76 | RCT, Open-label | Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253 |
| NCT04925375 Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease | Interstitial Lung Disease, Common Variable Immunodeficiency | P2 | Recruiting | 38 | RCT, Double-blind | Abatacept |
| NCT02393794 Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Triple-Negative Breast Cancer, Breast Cancer | P1P2 | Active | 51 | Open-label | Romidepsin, Cisplatin, Nivolumab |
| NCT04159818 Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | Metastatic Breast Cancer | P2 | Recruiting | 52 | RCT, Open-label | Nivolumab, Cisplatin, Low dose doxorubicin |
| NCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | Multiple Myeloma | P2 | Active | 67 | Open-label | Elotuzumab, Dexamethasone, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab |
| NCT04599140 SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | P1P2 | Active | 51 | Open-label | CXCR1/2 Inhibitor SX-682, Nivolumab |
| NCT07096297 Luspatercept + Darbepoetin in MDS | MDS (Myelodysplastic Syndrome) | P2 | Recruiting | 60 | Open-label | Luspatercept, Darbeopoetin |
| NCT03085173 A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Chronic Lymphocytic Leukemia (CLL), Relapsed | P1 | Active | 39 | Open-label | EGFRt/19-28z/4-1BBL CAR T cells |
| NCT06764771 A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Advanced Malignant Tumors | P1 | Active | 437 | Open-label | BMS-986488, Adagrasib, Cetuximab, Nivolumab |
| NCT06419634 Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Acute Myeloid Leukemia, Myelodysplastic Syndrome | P1 | Recruiting | 105 | Open-label | BMS-986497, Azacitidine, Venetoclax |
| NCT04606316 Surgical Nivolumab And Ipilimumab For Recurrent GBM | Glioblastoma, GBM | P1 | Active | 63 | RCT, Double-blind | Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab |
| NCT07061288 A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia | Schizophrenia | P1 | Recruiting | 48 | Open-label | KarXT |
| NCT06067841 A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | P1 | Recruiting | 140 | Open-label | BMS-986460 |
| NCT06121843 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Recruiting | 147 | Open-label | BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab |
| NCT03044613 Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | Gastric Cancer, Esophageal Cancer | P1 | Active | 32 | Open-label | Nivolumab, Relatlimab, Carboplatin, Paclitaxel |
| NCT04162015 A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | Malignant Pleural Mesothelioma | P1 | Active | 22 | Open-label | Nivolumab, Pemetrexed, Cisplatin or Carboplatin |
| NCT05334719 A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer | Stomach Neoplasms | Active | 500 | — | — | |
| NCT05779592 A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma | Muscle-invasive Urothelial Carcinoma | Active | 400 | — | — | |
| NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | HIV Infections, Hepatitis B | Recruiting | 24,258 | — | — | |
| NCT05909501 Assessment of Geriatric Evaluations Impact on New AML Guidance | AML, Adult | Recruiting | 100 | — | — | |
| NCT07008820 Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan | Myelodysplastic Syndrome (MDS) | Recruiting | 50 | — | — | |
| NCT05560399 A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | Early P1 | Active | 7 | Open-label | Iberdomide, Elotuzumab, Dexamethasone |
| NCT06698887 A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea | Multiple Myeloma | Recruiting | 15 | — | Idecabtagene vicleucel | |
| NCT05715463 Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity | Rheumatoid Arthritis, Palindromic Arthritis | N/A | Active | 101 | RCT, Open-label | — |
| NCT07256015 Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | Psoriasis | Recruiting | 200 | — | Deucravacitinib | |
| NCT03455452 Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer | Renal Cell Carcinoma, Renal Cell Cancer | Active | 600 | — | — | |
| NCT06146660 A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy | Recruiting | 600 | — | Mavacamten | |
| NCT07107373 A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Active | 150 | — | Mavacamten | |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT04919122 Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Active | 468 | — | — | |
| NCT07481110 Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria | Gastric Cancer, Gastric (Stomach) Cancer | Recruiting | 1,000 | — | — | |
| NCT06357754 Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia | Recruiting | 50 | — | Idecabtagene vicleucel, Lisocabtagene maraleucel | |
| NCT04794010 A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | Active | 825 | — | — | |
| NCT05851365 Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | Prostate Cancer, Localized Prostate Carcinoma | Early P1 | Active | 1 | Open-label | Hyperpolarized Bicarbonate (13C) |
| NCT07379827 Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) | Schizophrenia | Recruiting | 1,500 | — | Xanomeline and trospium chloride (KarXT) | |
| NCT05939700 Mavacamten Pregnancy Surveillance Program | Breastfeeding, Hypertrophic Cardiomyopathy | Recruiting | 20 | — | Mavacamten | |
| NCT05516537 Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments. | Multiple Sclerosis | N/A | Recruiting | 100 | RCT, Single-blind | — |
| NCT06154902 Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel | Multiple Myeloma | Active | 350 | — | Idecabtagene vicleucel | |
| NCT01758198 Abatacept Post-marketing Clinical Study in Japan | Rheumatoid Arthritis | P4 | Completed | 405 | RCT, Double-blind | Abatacept, Placebo matching with Abatacept, Methotrexate |
| NCT02464969 Apixaban for the Acute Treatment of Venous Thromboembolism in Children | Venous Thromboembolism | P4 | Completed | 229 | RCT, Open-label | Apixaban, Standard of Care |
| NCT02958969 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | Venous Thromboembolism, Multiple Myeloma | P4 | Completed | 50 | Open-label | Apixaban |
| NCT00207142 Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) | HIV Infections | P4 | Completed | 252 | RCT, Open-label | Atazanavir + 2 NRTIs, Atazanavir + Ritonavir + 2 NRTIs |
| NCT02939365 Precision Medicine Offers Belatacept Monotherapy | Transplantation | P4 | Withdrawn | — | Open-label | Belatacept |
| NCT00799045 Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects | Migraine | P4 | Completed | 220 | RCT, Double-blind | Clopidogrel |
| NCT02557100 Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis | Rheumatoid Arthritis | P4 | Completed | 80 | RCT, Single-blind | Abatacept, Adalimumab, Methotrexate |
| NCT03619876 Effects of Abatacept on Myocarditis in Rheumatoid Arthritis | Rheumatoid Arthritis, Myocardial Inflammation | P4 | Terminated | 11 | RCT, Open-label | Abatacept, Adalimumab |
| NCT01158703 Aspirin and Plavix Following Coronary Artery Bypass Grafting | Coronary Graft Patency | P4 | Terminated | 20 | RCT, Double-blind | clopidogrel, sugar pill, Aspirin |
| NCT01864174 Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P4 | Completed | 1,736 | RCT, Double-blind | Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR |
| NCT00447070 Effect of Atazanavir on Endothelial Function in HIV-Infected Patients | HIV Infections, Dyslipidemia | P4 | Completed | 50 | RCT, Single-blind | ATAZANAVIR |
| NCT00223496 12- Week Open Label Treatment of Refractory Bipolar Depression | Bipolar Disorder | P4 | Completed | 32 | Open-label | Aripiprazole |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT03590743 Calf Deep Vein Thrombosis Treatment Trial | Deep Vein Thrombosis | P4 | Terminated | 5 | RCT, Double-blind | Apixaban |
| NCT00867048 Strategic Timing of Antiretroviral Treatment | HIV Infection | P4 | Completed | 4,688 | RCT, Open-label | All licensed antiretroviral medications |
| NCT00362258 I PREVENT - Irbesartan In Hypertensive Diabetic Patients | Hypertension | P4 | Completed | 797 | Open-label | Irbesartan (Aprovel) |
| NCT02982954 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | Renal Cell Carcinoma | P4 | Completed | 211 | Open-label | Nivolumab, Ipilimumab |
| NCT06188637 Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study | Ulcerative Colitis | P4 | Withdrawn | — | Open-label | Ozanimod Oral Capsule |
| NCT00508157 A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome | Metabolic Syndrome, Schizophrenia | P4 | Terminated | 125 | RCT, Open-label | Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine) |
| NCT00365612 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients | HIV Infections | P4 | Completed | 300 | RCT, Open-label | Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) |
| NCT07459543 A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India | Untreated Melanoma, Unresectable Melanoma | P4 | Not Yet Recruiting | 30 | Open-label | Nivolumab + Relatlimab |
| NCT02041533 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Stage IV or Recurrent Non-Small Cell Lung Cancer | P3 | Completed | 541 | RCT, Open-label | Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed |
| NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | P3 | Completed | 743 | RCT, Open-label | Nivolumab, Sorafenib |
| NCT02569242 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | Esophageal Cancer | P3 | Completed | 419 | RCT, Open-label | Nivolumab, Docetaxel/Paclitaxel |
| NCT02743494 An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer | Advanced Cancer | P3 | Completed | 794 | RCT, Double-blind | Nivolumab |
| NCT03143153 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | Various Advanced Cancer | P3 | Completed | 970 | RCT, Open-label | Nivolumab, Ipilimumab, Cisplatin, Fluorouracil |
| NCT03138499 A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, | Hodgkin's Disease | P3 | Terminated | 23 | RCT, Open-label | Nivolumab, Brentuximab vedotin |
| NCT02617589 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Brain Cancer | P3 | Completed | 560 | RCT, Open-label | Nivolumab, Temozolomide |
| NCT02667587 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Brain Neoplasms | P3 | Completed | 716 | RCT, Double-blind | Nivolumab, Temozolomide |
| NCT02722694 A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Rheumatoid Arthritis (RA) | P3 | Unknown | 360 | RCT, Double-blind | Subcutaneous(SC) Abatacept, Methotrexate |
| NCT02864251 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | Non-Small-Cell Lung Carcinoma | P3 | Completed | 367 | RCT, Open-label | Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin |
| NCT02477826 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | P3 | Completed | 2,747 | RCT, Open-label | Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel |
| NCT02388906 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma | Melanoma | P3 | Completed | 906 | RCT, Double-blind | Ipilimumab, Nivolumab |
| NCT02998528 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | P3 | Completed | 505 | RCT, Open-label | Nivolumab, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab |
| NCT03414983 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | Colorectal Cancer | P2P3 | Completed | 196 | RCT, Open-label | Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab |
| NCT02481830 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | Lung Cancer | P3 | Completed | 569 | RCT, Open-label | Nivolumab, Topotecan, Amrubicin |
| NCT02538666 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | Lung Cancer | P3 | Completed | 907 | RCT, Double-blind | Nivolumab, Ipilimumab |
| NCT02105636 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | Squamous Cell Carcinoma of the Head and Neck | P3 | Completed | 361 | RCT, Open-label | Nivolumab, Cetuximab, Methotrexate, Docetaxel |
| NCT02231749 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | P3 | Completed | 1,390 | RCT, Open-label | Nivolumab, Ipilimumab, Sunitinib |
| NCT03349710 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | P3 | Completed | 74 | RCT, Open-label | Nivolumab, Cetuximab, Cisplatin |
| NCT02741570 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer | P3 | Completed | 947 | RCT, Open-label | Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil |
| NCT02872116 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Gastric Cancer, Gastroesophageal Junction Cancer | P3 | Completed | 2,031 | RCT, Open-label | Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil |
| NCT02899299 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | Mesothelioma | P3 | Completed | 605 | RCT, Open-label | Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin |
| NCT03117049 Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | Non-Small Cell Lung Cancer | P3 | Completed | 550 | RCT, Double-blind | ONO-4538, Carboplatin, Paclitaxel, Bevacizumab, Placebo |
| NCT01668784 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | P3 | Completed | 821 | RCT, Open-label | Nivolumab, Everolimus |
| NCT01835470 Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan | Juvenile Idiopathic Arthritis | P3 | Completed | 23 | Open-label | Abatacept |
| NCT05919823 A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Schizophrenia | P3 | Completed | 202 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT03006705 Study of Adjuvant ONO-4538 With Resected Gastric Cancer | Gastric Cancer | P3 | Completed | 800 | RCT, Double-blind | Nivolumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Capecitabine, Placebo |
| NCT00000637 A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children | HIV Infections | P3 | Completed | 819 | Double-blind | Zidovudine, Didanosine |
| NCT00289263 Maintenance Chemotherapy in Metastatic Breast Cancer | Breast Cancer | P3 | Unknown | 524 | RCT, Open-label | Paclitaxel |
| NCT06572449 Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | Schizophrenia | P3 | Completed | 173 | Open-label | KarXT |
| NCT00929864 Abatacept Versus Adalimumab Head-to-Head | Rheumatoid Arthritis | P3 | Completed | 869 | RCT, Single-blind | Abatacept, Adalimumab |
| NCT00123487 Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | P3 | Completed | 638 | RCT, Open-label | dasatinib, dasatinib |
| NCT00357370 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes | Type 2 Diabetes | P2P3 | Completed | 163 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT02726581 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | Multiple Myeloma | P3 | Completed | 170 | RCT, Open-label | Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone |
| NCT02032875 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant | Hepatitis C | P3 | Completed | 116 | Open-label | Daclatasvir, Sofosbuvir, Ribavirin |
| NCT00528372 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise | Type 2 Diabetes | P3 | Completed | 1,067 | RCT, Double-blind | Dapagliflozin, Dapagliflozin placebo, Metformin |
| NCT07284745 A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism | Irritability Associated With Autism Spectrum Disorder | P3 | Not Yet Recruiting | 176 | RCT, Double-blind | KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo |
| NCT01434186 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone | Diabetes Mellitus, Type 2 | P3 | Completed | 32 | RCT, Double-blind | Placebo matching with Saxagliptin, Metformin IR, Metformin XR, Saxagliptin |
| NCT01844505 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | Unresectable or Metastatic Melanoma | P3 | Completed | 945 | RCT, Double-blind | Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab |
| NCT02905266 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | Melanoma | P3 | Completed | 106 | RCT, Open-label | Nivolumab, Ipilimumab |
| NCT02170727 A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 | Hepatitis C Virus | P3 | Completed | 199 | Open-label | DCV/ASV/BMS-791325 |
| NCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery | Non-Small Cell Lung Cancer (NSCLC) | P3 | Completed | 925 | RCT, Open-label | nivolumab, ipilimumab, durvalumab |
| NCT05558319 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | Newly Diagnosed Multiple Myeloma | P3 | Not Yet Recruiting | 480 | RCT, Open-label | Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone |
| NCT01730534 Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events | Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event | P3 | Completed | 17,190 | RCT, Double-blind | Dapagliflozin 10 mg, Placebo tablet |
| NCT01003990 Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access | HIV | P3 | Completed | 710 | Open-label | Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine, Lopinavir/ritonavir |
| NCT02032901 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV | Hepatitis C | P3 | Completed | 173 | Open-label | Daclatasvir, Sofosbuvir |
| NCT01294423 Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes, High Blood Sugar | P3 | Completed | 261 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Placebo |
| NCT01142726 Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 511 | RCT, Double-blind | Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo |
| NCT03192215 AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke | Stroke | P3 | Terminated | 1,015 | RCT, Double-blind | Apixaban, Aspirin |
| NCT02460068 A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis | Brain Metastases | P3 | Unknown | 168 | RCT, Open-label | Fotemustine, Fotemustine and Ipilimumab, Ipilimumab and nivolumab |
| NCT00317915 Irbesartan in Type 2 Diabetes | Type 2 Diabetes, Microalbuminuria | P3 | Completed | — | RCT, Double-blind | Irbesartan treatment |
| NCT03085797 Effect of Mepolizumab in Severe Bilateral Nasal Polyps | Nasal Polyps | P3 | Completed | 414 | RCT, Double-blind | Mepolizumab, Placebo, Mometasone furoate |
| NCT04820309 An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) | Schizophrenia | P3 | Completed | 566 | Open-label | Xanomeline and Trospium Chloride Capsules |
| NCT00135382 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen | HIV Infections | P3 | Completed | 254 | RCT, Open-label | Videx EC, Epivir, Sustiva |
| NCT00673231 Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin | Type 2 Diabetes | P3 | Completed | 1,240 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Dapagliflozin, Placebo, Dapagliflozin, Dapagliflozin |
| NCT01497834 A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients | Hepatitis C | P3 | Completed | 224 | Open-label | BMS-790052 (Daclatasvir), BMS-650032 (Asunaprevir) |
| NCT01891643 PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | Newly Diagnosed, Previously Untreated Multiple Myeloma | P3 | Terminated | 23 | RCT, Open-label | Lenalidomide, Dexamethasone, Elotuzumab |
| NCT00643201 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism | Venous Thrombosis | P3 | Completed | 5,614 | RCT, Double-blind | Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban |
| NCT03632187 Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS | Polymyalgia Rheumatica | P3 | Unknown | 34 | RCT, Double-blind | Abatacept, Placebos |
| NCT01673867 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | Non-Squamous Cell Non-small Cell Lung Cancer | P3 | Completed | 582 | RCT, Open-label | Nivolumab, Docetaxel |
| NCT00984867 Dapagliflozin DPPIV Inhibitor add-on Study | Type 2 Diabetes | P3 | Completed | 833 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT00051038 Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients | Hepatitis B | P2P3 | Completed | — | — | Entecavir |
| NCT01860976 Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis | Psoriatic Arthritis | P3 | Completed | 489 | RCT, Double-blind | Abatacept, Placebo |
| NCT00243178 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W) | Atrial Fibrillation, Vascular Risk | P3 | Terminated | 6,706 | RCT, Open-label | clopidogrel (SR25990C) |
| NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 | Coronavirus, Covid19 | P2P3 | Completed | 4,044 | RCT, Double-blind | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg |
| NCT02496078 A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection | Hepatitis C | P3 | Completed | 207 | RCT, Double-blind | Daclatasvir, Asunaprevir |
| NCT07441408 Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis | Pulmonary Fibrosis | P3 | Not Yet Recruiting | 2,277 | Open-label | BMS-986278 |
| NCT01754974 Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C | Hepatitis C Virus (HCV) | P3 | Completed | 40 | RCT, Double-blind | Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a |
| NCT00296218 ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation | Myocardial Ischemia, Hypertension | P3 | Completed | 440 | RCT, Double-blind | Irbesartan |
| NCT00160329 Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia | Hyperlipidemia, HIV Infections | P3 | Completed | 60 | RCT, Open-label | Atazanavir |
| NCT03879122 A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer | P2P3 | Unknown | 135 | RCT, Open-label | Ipilimumab 5 MG/ML, Nivolumab 10 MG/ML, Docetaxel, ADT (androgen deprivation therapy) |
| NCT00855166 Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 182 | RCT, Double-blind | Dapagliflozin, Metformin, Sitagliptin, Placebo |
| NCT01031680 Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension | Type 2 Diabetes Mellitus, Cardiovascular Disease | P3 | Completed | 922 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT00330772 Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study | Coronary Artery Disease, Coronary Artery Bypass Grafting | P3 | Completed | 150 | RCT, Double-blind | Aspirin, Clopidogrel |
| NCT00002429 Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen | HIV Infections | P3 | Completed | 500 | — | Lamivudine/Zidovudine, Nelfinavir mesylate, Stavudine, Didanosine |
| NCT01718145 A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects | Hepatitis C Virus Infection | P3 | Completed | 258 | RCT, Open-label | Daclatasvir, Asunaprevir, Ribavirin, pegIFNα-2b, Telaprevir |
| NCT00123474 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | Myeloid Leukemia, Chronic, Chronic-Phase | P3 | Completed | 724 | RCT, Open-label | dasatinib, dasatinib, dasatinib, dasatinib |
| NCT00395018 Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection | Hepatitis B, Chronic | P3 | Completed | 109 | Open-label | entecavir |
| NCT00975091 Continue Entecavir Rollover From China | Chronic Hepatitis B Virus | P3 | Completed | 600 | Open-label | Entecavir, Entecavir |
| NCT01931150 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT | Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma | P3 | Completed | 11 | RCT, Double-blind | Topical Dapsone 5% Gel, oral antibiotics |
| NCT00094991 Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 42 | RCT, Double-blind | Muraglitazar |
| NCT00095823 A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 1,200 | RCT, Double-blind | Antidepressant + Placebo, Antidepressant + Aripiprazole |
| NCT00048581 Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | Rheumatoid Arthritis | P3 | Completed | 738 | RCT, Double-blind | Abatacept, Placebo, Abatacept |
| NCT05297565 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection | Melanoma | P3 | Completed | 14 | RCT, Open-label | Nivolumab/rHuPH20, Nivolumab |
| NCT00095173 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | Juvenile Rheumatoid Arthritis | P3 | Completed | 214 | RCT, Double-blind | Abatacept, Placebo, Abatacept |
| NCT06947941 A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) | Alzheimer Disease, Psychosis | P3 | Not Yet Recruiting | 1,046 | RCT, Double-blind | KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo |
| NCT00410202 Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus | Hepatitis B, Chronic | P3 | Completed | 629 | RCT, Open-label | Entecavir, Tenofovir, Adefovir, Lamivudine |
| NCT01866930 Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV | Chronic Hepatitis C Infection | P3 | Terminated | 453 | Open-label | Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV) |
| NCT01448044 Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C | Hepatitis C | P3 | Completed | 152 | RCT, Double-blind | BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin |
| NCT00556140 The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression | Psychotic Depression | P3 | Completed | 16 | Open-label | Aripiprazole |
| NCT05145413 A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | Schizophrenia | P3 | Completed | 396 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo |
| NCT07285798 A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder | P3 | Not Yet Recruiting | 176 | RCT, Double-blind | KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo |
| NCT00663260 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment | Diabetes Mellitus, Type 2 | P2P3 | Completed | 631 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Placebo |
| NCT02857426 A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | Lymphoma | P2 | Completed | 66 | Open-label | Nivolumab |
| NCT02387996 A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | Various Advanced Cancer | P2 | Completed | 270 | Open-label | Nivolumab |
| NCT02488759 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | Various Advanced Cancer | P1P2 | Completed | 578 | RCT, Open-label | Nivolumab, Ipilimumab, Relatlimab, Daratumumab |
| NCT02913313 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | Broad Solid Tumor | P1P2 | Completed | 101 | Open-label | BMS-986207, Nivolumab, Ipilimumab |
| NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Hepatocellular Carcinoma | P1P2 | Completed | 657 | Open-label | Nivolumab, Sorafenib, Ipilimumab, Cabozantinib |
| NCT04704154 A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Solid Tumors | P2 | Completed | 175 | Open-label | Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo) |
| NCT00279409 Treatment of Children With ADHD Who do Not Fully Respond to Stimulants | Attention Deficit Hyperactivity Disorder | P2 | Terminated | 10 | RCT, Double-blind | aripiprazole, Sugar pill |
| NCT02705105 Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | Solid Tumor, Cancer | P1P2 | Completed | 114 | Open-label | Mogamulizumab + Nivolumab |
| NCT03090737 Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | P2 | Completed | 129 | Open-label | Nivolumab |
| NCT02027298 Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome | P2 | Withdrawn | — | Open-label | Abatacept |
| NCT00780000 Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer | Breast Cancer | P2 | Terminated | 4 | Open-label | Alvespimycin |
| NCT00320255 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer | Thrombosis, Cancer | P2 | Completed | 130 | RCT, Double-blind | Apixaban, Placebo |
| NCT00000807 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy | Sarcoma, Kaposi, HIV Infections | P2 | Completed | 41 | Open-label | Etoposide |
| NCT03149120 Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | Soft Tissue Sarcomas | P2 | Withdrawn | — | RCT, Open-label | Nivolumab, Pazopanib |
| NCT02638948 Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 508 | RCT, Double-blind | BMS-986142, Placebo, Methotrexate |
| NCT05236608 A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | Metastatic Non Small Cell Lung Cancer | P1P2 | Unknown | 53 | Open-label | Nivolumab, ADG106 |
| NCT00534313 Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis | Psoriatic Arthritis | P2 | Terminated | 191 | RCT, Double-blind | Abatacept, Placebo |
| NCT00633789 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma | P2 | Completed | 597 | RCT, Double-blind | brivanib, Placebo |
| NCT06247540 Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | P2 | Withdrawn | — | Open-label | Nivolumab, Rituximab, Venetoclax |
| NCT00895297 Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia | Chronic Myeloid Leukemia | P2 | Terminated | 50 | Open-label | Dasatinib (Sprycel) |
| NCT03825367 Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | AML, Childhood | P1P2 | Unknown | 13 | Open-label | Nivolumab, 5-azacytidine |
| NCT02970981 Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | Melanoma | P2 | Completed | 18 | Open-label | Nivolumab, Ipilimumab |
| NCT02124044 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV | HIV-HCV | P2 | Completed | 30 | Open-label | Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325 |
| NCT03770299 An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma | P2 | Withdrawn | — | RCT, Open-label | Nivolumab, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel |
| NCT00251485 A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer | Colorectal Cancer | P2 | Completed | 82 | Open-label | Cetuximab |
| NCT04918147 Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) | IgG4 Related Disease, IgG4-RD | P2 | Terminated | 8 | RCT, Double-blind | elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone |
| NCT02320058 An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself | Melanoma | P2 | Completed | 119 | Open-label | Ipilimumab, Nivolumab |
| NCT03146650 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma | P2 | Unknown | 25 | Open-label | Ipilimumab, Nivolumab |
| NCT01125189 Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients | Hepatitis C Virus | P2 | Completed | 558 | RCT, Double-blind | Daclatasvir, Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin |
| NCT00423891 A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection | Hepatitis B, Chronic | P1P2 | Completed | 64 | Open-label | Entecavir |
| NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | Prostate Cancer, Recurrent Prostate Cancer | P2 | Completed | 8 | Open-label | Nivolumab |
| NCT00344552 Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer | Esophageal Cancer | P2 | Completed | 53 | Open-label | Paclitaxel |
| NCT03527264 BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer | Cervical Cancer | P2 | Terminated | 4 | Open-label | Nivolumab induction, Cisplatin, Nivolumab with chemoradiation, Nivolumab maintenance |
| NCT00874770 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) | Hepatitis C Infection | P2 | Completed | 74 | RCT, Double-blind | Daclatasvir, Daclatasvir, Daclatasvir, Placebo, Peginterferon alpha-2a, ribavirin |
| NCT00821886 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer | Breast Cancer | P2 | Completed | 60 | Open-label | Ixabepilone, Trastuzumab, Carboplatin |
| NCT01592370 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Non-Hodgkin's Lymphoma, Hodgkin Lymphoma | P1P2 | Completed | 320 | RCT, Open-label | Nivolumab, Ipilimumab, Lirilumab, Daratumumab, Pomalidomide, Dexamethasone |
| NCT03590210 Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas | Metastatic Adult Soft Tissue Sarcoma | P2 | Completed | 92 | Open-label | Trabectedin, Nivolumab |
| NCT02659059 Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer | Non-Small-Cell Lung Cancer | P2 | Completed | 324 | Open-label | Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy |
| NCT01420770 Phase 2 Study of SAR302503 in Patients With Myelofibrosis | Hematopoietic Neoplasm | P2 | Completed | 30 | RCT, Open-label | SAR302503 |
| NCT01928394 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | P1P2 | Completed | 1,163 | RCT, Open-label | Nivolumab, Ipilimumab, Cobimetinib |
| NCT00128856 Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | Breast Cancer | P2 | Completed | 46 | Open-label | Gemcitabine, Adriamycine, Paclitaxel |
| NCT00216203 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1P2 | Completed | 36 | Open-label | Pemetrexed, Cetuximab |
| NCT03486912 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis | Hepatic Cirrhosis, Liver Fibrosis | P2 | Completed | 155 | RCT, Double-blind | BMS-986036 |
| NCT03668119 A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | Pan Tumor | P2 | Completed | 212 | RCT, Open-label | Nivolumab, Ipilimumab |
| NCT02654132 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | Multiple Myeloma | P2 | Completed | 117 | RCT, Open-label | Elotuzumab, Pomalidomide, Dexamethasone |
| NCT02243371 GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Previously Treated Metastatic Adenocarcinoma of the Pancreas | P2 | Completed | 93 | RCT, Open-label | CRS-207, CRS-207, nivolumab, GVAX, CY |
| NCT01783938 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | Advanced or Metastatic Melanoma | P2 | Completed | 138 | RCT, Open-label | Nivolumab, Ipilimumab |
| NCT03572478 Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Prostate Cancer, Endometrial Cancer | P1P2 | Terminated | 12 | RCT, Open-label | Rucaparib, Nivolumab |
| NCT00355238 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | Hepatocellular Carcinoma (HCC) | P2 | Completed | 137 | Open-label | brivanib (active) |
| NCT01928576 Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | Non-Small Cell Lung Cancer, Epigenetic Therapy | P2 | Completed | 143 | RCT, Open-label | Azacitidine, Entinostat, Nivolumab, CC-486 300 |
| NCT03695250 BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | P1P2 | Terminated | 8 | Open-label | IDO1 Inhibitor BMS-986205, Nivolumab |
| NCT01498978 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | P2 | Completed | 10 | Open-label | ipilimumab |
| NCT00381706 Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | Esophageal Cancer | P2 | Completed | 245 | RCT, Open-label | cetuximab, ECF, IC, FOLFOX |
| NCT06532136 Deucravacitinib Rosacea | Papulopustular Rosacea | P2 | Withdrawn | — | RCT, Double-blind | Deucravacitinib, Placebo |
| NCT01030432 Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin | Hepatitis C Virus | P2 | Completed | 285 | RCT, Double-blind | BMS-650032, BMS-650032, Placebo, Placebo, Placebo, Peginterferon Alfa-2a, Peginterferon Alfa-2a, Ribavirin, Ribavirin |
| NCT03219671 Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | Classic Kaposi Sarcoma | P2 | Unknown | 20 | Open-label | Nivolumab, Ipilimumab |
| NCT01167244 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response | Non-Small-Cell Lung Carcinoma | P2 | Completed | 11 | Open-label | BMS-690514 |
| NCT02939300 Ipilimumab and Nivolumab in Leptomeningeal Metastases | Leptomeningeal Carcinomatosis | P2 | Completed | 18 | Open-label | Nivolumab, Ipilimumab |
| NCT00289640 Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | Melanoma | P2 | Completed | 210 | RCT, Double-blind | ipilimumab (MDX-010, BMS-734016), Ipilimumab, Ipilimumab |
| NCT00049257 Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | Prostate Cancer | P2 | Completed | 58 | Open-label | carboplatin, paclitaxel |
| NCT03829722 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Oropharynx Squamous Cell Carcinoma | P2 | Completed | 26 | Open-label | Nivolumab, Carboplatin, Paclitaxel |
| NCT00909766 Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects | Obesity | P1P2 | Completed | 113 | RCT, Double-blind | BMS-830216, BMS-830216, BMS-830216, BMS-830216, BMS-830216, BMS-830216, Placebo |
| NCT00007202 Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients | HIV Infections | P2 | Completed | 55 | — | Atazanavir, Stavudine, Didanosine |
| NCT04493203 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | Advanced Melanoma, Unresectable Melanoma | P2 | Completed | 31 | Open-label | Nivolumab, Axitinib |
| NCT00357461 Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | Melanoma (Skin) | P2 | Withdrawn | — | RCT, Open-label | gp100:209-217(210M) peptide vaccine, gp100:280-288(288V) peptide vaccine, incomplete Freund's adjuvant, ipilimumab |
| NCT03411031 Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | Multiple Myeloma | P2 | Terminated | 18 | RCT, Open-label | Elotuzumab, Lenalidomide, Dexamethasone |
| NCT01790594 Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation | Simultaneous Kidney and Pancreas Transplantation | P2 | Terminated | 46 | RCT, Open-label | Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit), Tacrolimus, Mycophenolate mofetil |
| NCT04098432 STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | P1P2 | Completed | 15 | Open-label | Nivolumab |
| NCT03214250 Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | P1P2 | Completed | 129 | RCT, Open-label | APX005M, Nivolumab, Nab-Paclitaxel, Gemcitabine |
| NCT05074992 A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma | Glioblastoma | P2 | Terminated | 1 | Open-label | Ipilimumab |
| NCT00196599 Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults | HIV Infections, Antiretroviral Naive | P2 | Completed | 39 | Open-label | emtricitabine, FTC (drug), didanosine, ddI (drug), efavirenz (drug) |
| NCT03161379 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | Pancreatic Cancer | P2 | Completed | 31 | Open-label | Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine |
| NCT03682276 Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1P2 | Unknown | 32 | Open-label | Ipilimumab, Nivolumab |
| NCT02409368 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | Non-Small Cell Lung Cancer | P2 | Completed | 812 | Open-label | Nivolumab |
| NCT03355482 MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE | Systemic Lupus Erythematosus Arthritis | P2 | Terminated | 9 | RCT, Double-blind | Methylprednisolone, Placebos |
| NCT02823574 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer | P2 | Completed | 425 | RCT, Double-blind | Nivolumab, Ipilimumab |
| NCT02450682 Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study | Atrial Fibrillation | P2 | Withdrawn | — | RCT, Open-label | Apixaban, Warfarin |
| NCT03029780 An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | Renal Cell Carcinoma | P2 | Completed | 104 | RCT, Open-label | Opdivo, Yervoy |
| NCT00084656 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | Intraocular Melanoma, Melanoma (Skin) | P2 | Completed | 77 | Open-label | ipilimumab, Tyrosinase/gp100/MART-1 Peptides |
| NCT04405102 COVID-19 Ozanimod Intervention Study | COVID-19 | P2 | Terminated | 43 | RCT, Open-label | Ozanimod |
| NCT01425970 Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin | Hepatitis C | P2 | Terminated | 210 | RCT, Double-blind | INX-08189, INX-08189, INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, INX-08189, Daclatasvir |
| NCT00564876 Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P2 | Terminated | 2 | Open-label | Dasatinib |
| NCT02038933 Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | Lymphoma. Non-Hodgkin | P2 | Completed | 121 | Open-label | Nivolumab |
| NCT03697252 A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia | Schizophrenia | P2 | Completed | 182 | RCT, Double-blind | Xanomeline and Trospium Chloride Capsules, Placebo Capsules |
| NCT00444678 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | Colorectal Cancer, Neoplasm Metastasis | P2 | Completed | 36 | Open-label | Cetuximab, Oxaliplatin, Capecitabine |
| NCT01030718 Rollover Study of BMS-354825 in Patients With CML and Ph+ALL | Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | P1P2 | Completed | 54 | Open-label | dasatinib |
| NCT00566618 Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | Breast Cancer, Bone Metastases | P1P2 | Completed | 31 | Open-label | Dasatinib, Zoledronic Acid |
| NCT01791491 Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients | Kidney Transplant | P2 | Completed | 16 | Open-label | Belatacept |
| NCT02423343 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | Solid Tumor, Non-Small Cell Lung Cancer Recurrent | P1P2 | Completed | 41 | Open-label | Galunisertib, Nivolumab |
| NCT03405155 Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Melanoma (Skin) | P2 | Completed | 26 | Open-label | Nivolumab |
| NCT00562419 CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | P2 | Unknown | 72 | RCT, Open-label | CT-322, irinotecan hydrochloride |
| NCT01142700 A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I | Chronic Hepatitis C Virus Genotype 1 | P2 | Withdrawn | — | RCT, Double-blind | BMS-824393, BMS-824393, BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin |
| NCT00225160 ALCAR Prophylaxis Study | HIV Infections, Distal Symmetric Polyneuropathy | P2 | Unknown | 50 | RCT, Double-blind | acetyl L-carnitine |
| NCT03329885 A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis | Rheumatoid Arthritis, Psoriasis | P1P2 | Terminated | 38 | RCT, Double-blind | BMS-986251 |
| NCT02341625 A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | Advanced Cancer | P1P2 | Terminated | 126 | Open-label | BMS-986148, Nivolumab |
| NCT03554317 COMbination of Bipolar Androgen Therapy and Nivolumab | Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | P2 | Completed | 45 | Open-label | Testosterone cypionate, Nivolumab |
| NCT07492680 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | Solid Tumors | P2 | Not Yet Recruiting | 260 | Open-label | BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel |
| NCT01323517 Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | Melanoma | P2 | Completed | 26 | Open-label | Ipilimumab, Melphalan and Dactinomycin |
| NCT02481297 Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | Leukemia, Chronic Lymphocytic Leukemia | P2 | Completed | 7 | Open-label | Lirilumab, Rituximab |
| NCT03994601 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Advanced Cancer | P1P2 | Completed | 219 | RCT, Open-label | BMS-986288, Nivolumab, Regorafenib |
| NCT04118166 Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | Soft Tissue Sarcoma | P2 | Completed | 30 | Open-label | Ipilimumab, Nivolumab |
| NCT02960230 H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | Diffuse Intrinsic Pontine Glioma, Glioma | P1P2 | Completed | 50 | Open-label | K27M peptide, Nivolumab |
| NCT01673854 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | Melanoma | P2 | Completed | 70 | Open-label | Ipilimumab, Vemurafenib |
| NCT00057473 A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors | Neoplasms | P2 | Completed | — | RCT, Open-label | carboplatin + irinotecan, irinotecan |
| NCT00545766 Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | Prostate Cancer | P2 | Completed | 41 | Open-label | Vinflunine |
| NCT01423695 Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Completed | 121 | Open-label | paclitaxel plus trastuzumab |
| NCT00468169 Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer | Head and Neck Cancer | P2 | Completed | 110 | RCT, Open-label | Cetuximab, 5-FU, Hydroxyurea, Cisplatin |
| NCT03333746 Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | P2 | Terminated | 1 | Open-label | Lenalidomide, Nivolumab |
| NCT00279760 Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis | Rheumatoid Arthritis | P1P2 | Completed | 210 | RCT, Double-blind | Belatacept, Abatacept |
| NCT02556086 A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) | Hepatitis C | P2 | Withdrawn | — | Open-label | Daclatasvir, Sofosbuvir |
| NCT04877990 A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis | Crohn Disease, Ulcerative Colitis | P2 | Completed | 67 | Open-label | Deucravacitinib |
| NCT00619190 Study of Aripiprazole to Treat Children and Adolescents With Autism | Autistic Disorder, Asperger Syndrome | P2 | Completed | 30 | Open-label | aripiprazole |
| NCT01097642 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients | Breast Cancer | P2 | Completed | 40 | RCT, Open-label | Cetuximab, Ixabepilone |
| NCT02428855 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma | P2 | Completed | 8 | Open-label | Dasatinib |
| NCT04197310 Cabozantinib and Nivolumab for Carcinoid Tumors | Carcinoid Tumor, Carcinoid Tumor of GI System | P2 | Completed | 19 | Open-label | Nivolumab, Cabozantinib |
| NCT03949153 Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis | Melanoma (Skin) | P1P2 | Completed | 19 | Open-label | Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Ipilimumab Injection |
| NCT02917772 Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma | Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | P2 | Completed | 200 | Open-label | Nivolumab/Ipilimumab |
| NCT04377997 Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19 | Cardiovascular Diseases, COVID-19 | P2 | Unknown | 300 | RCT, Open-label | Enoxaparin |
| NCT03121417 Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | P2 | Withdrawn | — | Open-label | Nivolumab |
| NCT02750514 An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | Advanced Cancer | P2 | Terminated | 295 | RCT, Open-label | Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205 |
| NCT03934216 Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 131 | RCT, Double-blind | BMS-986165 |
| NCT00284154 Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | Carcinoma, Small Cell, Lung Cancer | P2 | Completed | 51 | Open-label | Vinflunine |
| NCT01593254 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib | Chronic Phase Chronic Myeloid Leukemia | P2 | Completed | 262 | RCT, Open-label | Imatinib, Dasatinib |
| NCT07212062 The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. | Alzheimers Disease | P2 | Not Yet Recruiting | 60 | RCT, Double-blind | X/T + X-EC, Placebo, Lecanemab 10 mg/kg |
| NCT05066607 Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | AL Amyloidosis | P2 | Unknown | 46 | Open-label | Isatuximab |
| NCT04042116 A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Advanced Solid Tumor, Gynecologic Cancer | P1P2 | SUSPENDED | 227 | Open-label | Lucitanib, Lucitanib, Lucitanib, Nivolumab |
| NCT03400163 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis | P2 | Completed | 3 | RCT, Double-blind | BMS-986036, Placebo |
| NCT01020565 A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection | Chronic Hepatitis B | P2 | Completed | 60 | RCT, Double-blind | Entecavir |
| NCT02270957 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches | Systemic Lupus Erythematosus | P2 | Completed | 66 | RCT, Double-blind | Abatacept |
| NCT03623854 Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Chordoma, Locally Advanced Chordoma | P2 | Completed | 10 | Open-label | Nivolumab, Relatlimab |
| NCT02985957 A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | Prostate Cancer | P2 | Completed | 351 | RCT, Open-label | Nivolumab, Ipilimumab, Cabazitaxel, Prednisone |
| NCT01046422 Safety Study of BMS-770767 in Subjects With Type 2 Diabetes | Diabetes Type 2 | P2 | Completed | 76 | RCT, Double-blind | BMS-770767, BMS-770767, BMS-770767, BMS-770767, Placebo, Metformin |
| NCT00183898 Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | Gastric Cancer, Esophageal Cancer | P2 | Unknown | 75 | Open-label | oxaliplatin, capecitabine |
| NCT01602367 Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients | Hypertension | P2 | Terminated | 7 | RCT, Double-blind | BMS-823778, BMS-823778, BMS-823778, Placebo matching with BMS-823778 |
| NCT03241745 A Study of Nivolumab in Selected Uterine Cancer Patients | Uterine Cancer, Endometrial Carcinoma | P2 | Completed | 35 | Open-label | Nivolumab |
| NCT03456648 Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study | ESRD, Anticoagulant Toxicity | P2 | Completed | 24 | Open-label | apixaban |
| NCT03472586 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | P2 | Completed | 14 | Open-label | Ipilimumab, Nivolumab, Embolization Therapy |
| NCT04575922 Nivolumab+Ipilimumab+RT in MSS mCRC | Metastatic Microsatellite Stable Colorectal Cancer | P2 | Unknown | 32 | Open-label | Nivolumab, Ipilimumab |
| NCT00971945 Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | Breast Cancer | P2 | Completed | 6 | Open-label | Paclitaxel |
| NCT03436862 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | Hodgkin Lymphoma | P2 | Completed | 37 | Open-label | Nivolumab |
| NCT00001045 Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease | HIV Infections | P2 | Completed | 300 | — | Nevirapine, Zidovudine, Didanosine |
| NCT02551861 A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 | Hepatitis C | P2 | Withdrawn | — | RCT, Open-label | Daclatasvir, Sofosbuvir, Ribavirin |
| NCT02823990 TG4010 and Nivolumab in Patients With Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | P2 | Completed | 13 | Open-label | TG4010, Nivolumab |
| NCT03610490 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | P2 | Terminated | 16 | Open-label | Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2 |
| NCT00656890 A Study of MDX-1100 in Subjects With Active Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 110 | RCT, Double-blind | sterile saline for injection, MDX-1100 |
| NCT03149159 Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | P2 | Withdrawn | — | Open-label | Nivolumab, Ipilimumab |
| NCT02572167 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | Hodgkin Lymphoma | P1P2 | Completed | 93 | Open-label | brentuximab vedotin, nivolumab |
| NCT00086892 Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Ovarian Cancer, Primary Peritoneal Cavity Cancer | P2 | Completed | — | Open-label | cetuximab, carboplatin |
| NCT01752985 Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease | Diabetic Kidney Disease | P2 | Terminated | 319 | RCT, Double-blind | BMS-813160, Placebo matching with BMS-813160 |
| NCT02805010 Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously | Rheumatoid Arthritis (RA) | P1 | Unknown | 22 | RCT, Double-blind | Abatacept |
| NCT02534506 Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | Malignant Tumors | P1 | Completed | 18 | Open-label | Urelumab, Nivolumab |
| NCT03158272 A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | Advanced Malignancies | P1 | Completed | 19 | Open-label | Cabiralizumab, Nivolumab |
| NCT02966548 Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | Cancer | P1 | Completed | 35 | Open-label | Relatlimab, Nivolumab |
| NCT03745807 An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | Advanced Cancer | P1 | Completed | 3 | Open-label | NKTR-214, Nivolumab |
| NCT00730639 A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies | Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma | P1 | Completed | 395 | Open-label | BMS-936558 (MDX-1106), BMS-936558 (MDX-1106), BMS-936558 (MDX-1106), BMS-936558 (MDX-1106), BMS-936558 (MDX-1106) |
| NCT01472081 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | P1 | Completed | 194 | Open-label | Nivolumab, Pazopanib, Sunitinib, Ipilimumab |
| NCT03203876 A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | Advanced Cancer | P1 | Completed | 10 | Open-label | Lirilumab, Nivolumab, Ipilimumab |
| NCT02281058 Open-label Pilot Study of Abatacept for the Treatment of Vitiligo | Vitiligo | P1 | Unknown | 10 | Open-label | Abatacept |
| NCT03674476 An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function | NAFLD, Nonalcoholic Fatty Liver Disease | P1 | Completed | 40 | Open-label | BMS-986036 |
| NCT01755494 A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration | Type 2 Diabetes Mellitus(T2DM) | P1 | Completed | 64 | RCT, Open-label | Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg, Komboglyze XR 5/500 mg, Komboglyze XR 5/1000 mg |
| NCT03605719 Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | Recurrent Plasma Cell Myeloma | P1 | Completed | 23 | Open-label | Carfilzomib, Dexamethasone, Nivolumab, Pelareorep |
| NCT06088264 A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants | Healthy Male Participants | P1 | Completed | 8 | Open-label | BMS-986322 |
| NCT03038711 A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers | Ulcerative Colitis | P1 | Completed | 213 | RCT, Double-blind | BMS-986166 |
| NCT01763190 Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment | Renal Impairment | P1 | Completed | 36 | Open-label | SAR302503 |
| NCT00518297 DDI HV (ATV - Merck) | HIV Infections | P1 | Completed | 22 | Open-label | Raltegravir, Atazanavir, Atazanavir + Raltegravir |
| NCT03215810 Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | P1 | Completed | 20 | Open-label | Nivolumab, Cyclophosphamide, Fludarabine, Interleukin-2 (IL2) |
| NCT03891108 A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants | Heart Failure | P1 | Completed | 60 | RCT, Open-label | BMS-986231 Formulation A, BMS-986231 Formulation B, BMS-986231 Formulation C, BMS-986231 Formulation D |
| NCT01024231 Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | Malignant Melanoma | P1 | Completed | 127 | Open-label | BMS-936558 (MDX1106-04), Ipilimumab |
| NCT03660436 An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants | Healthy Participants | P1 | Completed | 131 | Open-label | BMS-986165, MMF |
| NCT03661632 An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Advanced Cancer | P1 | Completed | 27 | Open-label | BMS-986310, Nivolumab |
| NCT00362830 A Study of the Alternative Administration of Ixabepilone and Vinflunine | Cancer | P1 | Completed | 60 | Open-label | vinflunine + ixabepilone |
| NCT00729664 Multiple Ascending Dose (MDX1105-01) | Cancer, Multiple Indications | P1 | Completed | 281 | Open-label | Anti-PDL-1 antibody, Anti-PDL-1 antibody, Anti-PDL-1 antibody, Anti-PDL-1 antibody, Anti-PDL-1 antibody |
| NCT00508287 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes | Type 2 Diabetes | P1 | Completed | 36 | RCT, Double-blind | BMS-686117, Byetta, Placebo |
| NCT01042314 Drug-Drug Interaction Study With Aricept® (Donepezil) | Alzheimer Disease | P1 | Completed | 18 | Open-label | Donepezil, BMS-708163 |
| NCT03196206 Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment | Thrombosis | P1 | Completed | 24 | Open-label | BMS-986177 |
| NCT00362726 Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone | HIV Infections | P1 | Completed | 14 | Open-label | Rosiglitazone maleate, Atazanavir Sulphate, Atazanavir Sulphate + Rosiglitazone maleate, Atazanavir Sulphate + Ritonavir, Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate |
| NCT04934696 A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential | Healthy Participants | P1 | Completed | 25 | Open-label | BMS-986166, Oral contraceptive |
| NCT00705367 Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg | Lupus Nephritis | P1 | Completed | 13 | RCT, Double-blind | Placebo, Abatacept, Abatacept |
| NCT02897765 A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Urinary Bladder Cancer, Bladder Tumors | P1 | Completed | 34 | Open-label | NEO-PV-01, Nivolumab |
| NCT00000954 A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | Sarcoma, Kaposi, HIV Infections | P1 | Completed | 72 | — | Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zalcitabine, Didanosine |
| NCT04926051 A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption | Healthy Participants | P1 | Completed | 40 | RCT, Double-blind | BMS-986172 |
| NCT02831231 Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium | Schizophrenia | P1 | Completed | 70 | RCT, Double-blind | xanomeline tartrate, Trospium chloride |
| NCT01129375 Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects | Healthy | P1 | Completed | 72 | RCT, Double-blind | clopidogrel, placebo, omeprazole |
| NCT01340586 Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis | End Stage Renal Disease | P1 | Completed | 18 | Open-label | Apixaban, Apixaban |
| NCT05852769 A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants | Healthy Volunteers | P1 | Completed | 18 | Open-label | BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin |
| NCT00365339 Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir | HIV Infections | P1 | Completed | 40 | RCT, Open-label | Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine, Atazanavir+Ritonavir+Tenofovir+Famotidine, Atazanavir+Ritonavir+Tenofovir+Famotidine, Atazanavir+Ritonavir+Tenofovir+Famotidine |
| NCT03784040 Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | Gastric Cancer | P1 | Unknown | 40 | Open-label | OTSGC-A24, Nivolumab, Ipilimumab |
| NCT00732186 Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia | Leukemia, Myeloid, Chronic | P1 | Withdrawn | — | Open-label | Ipilimumab |
| NCT05524857 Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | Myeloproliferative Neoplasm | P1 | Terminated | 2 | Open-label | Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg |
| NCT04567667 Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants | Healthy Volunteers | P1 | Completed | 9 | Open-label | [14C] BMS-986278, Kinevac® |
| NCT06853171 Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders | Psychiatric Disorders | P1 | Completed | 24 | RCT, Open-label | KarXT, KarX-EC |
| NCT00501410 FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | Colorectal Cancer | P1 | Completed | 86 | Open-label | 5-FU, Cetuximab, Dasatinib, Leucovorin, Oxaliplatin |
| NCT05362045 A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants | Healthy Participants | P1 | Completed | 158 | RCT, Open-label | Mavacamten |
| NCT00207103 MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | Tumors, Neoplasm Metastasis | P1 | Completed | 68 | Open-label | Brivanib, Brivanib, Brivanib, Brivanib, Brivanib, Brivanab |
| NCT05952089 A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure | Heart Failure With Reduced Ejection Fraction | P1 | Completed | 13 | Open-label | Danicamtiv, Midazolam |
| NCT00560391 Dasatinib in Combination With Revlimid (and Dexamethasone) | Multiple Myeloma | P1 | Completed | 35 | Open-label | Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg |
| NCT00872976 Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P1 | Withdrawn | — | Open-label | Dasatinib, Combination of Bendamustine + Dasatinib, Dasatinib, Combination of Bendamustine + Dasatinib |
| NCT04540705 A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | Renal Cell Carcinoma | P1 | Completed | 30 | Open-label | Nivolumab, Axitinib, Cabozantinib |
| NCT02227173 A Phase 1 Drug-drug Interaction Study in Healthy Volunteers | Drug-drug Interaction Study | P1 | Completed | 20 | Open-label | BMS-986020, Montelukast, Flurbiprofen, Digoxin |
| NCT06746402 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants | Healthy Volunteers | P1 | Completed | 42 | RCT, Double-blind | BMS-986278, Placebo, Moxifloxacin |
| NCT06955741 A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants | Healthy Volunteer | P1 | Completed | 46 | RCT, Open-label | BMS-986446 IV, BMS-986446 SC, Acetaminophen, Loratadine |
| NCT02846376 Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant | Acute Myeloid Leukemia and Myelodysplastic Syndrome | P1 | Terminated | 8 | Open-label | Nivolumab, Ipilimumab |
| NCT01055691 A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets | Healthy Volunteers | P1 | Completed | 120 | RCT, Open-label | Dapagliflozin/Metformin, Dapagliflozin, Metformin, Dapagliflozin/Metformin, Dapagliflozin, Metformin |
| NCT04113668 The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants | Healthy Participants | P1 | Completed | 48 | Open-label | BMS-986165, diflunisal |
| NCT01629758 Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | Neoplasms by Site | P1 | Completed | 33 | Open-label | Denenicokin, Nivolumab |
| NCT05001152 Taste Assessment of Ozanimod | Healthy Volunteers | P1 | Completed | 7 | Open-label | Ozanimod |
| NCT03247283 Pharmacokinetics and Metabolism Study in Healthy Male Participants | Cancer | P1 | Completed | 9 | Open-label | BMS-986205 |
| NCT00479583 Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX | Cancer | P1 | Completed | 25 | Open-label | BMS-690514 / FOLFIRI, BMS-690514 / FOLFOX |
| NCT01146327 A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects | Healthy | P1 | Completed | 60 | RCT, Double-blind | PF-04620110, PF-04620110, PF-04620110, PF-04620110, Placebo |
| NCT00326131 A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer | Cancer | P1 | Terminated | 6 | Open-label | Oral Taxane |
| NCT03981094 A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF) | P1 | Completed | 22 | RCT, Open-label | BMS-986278, Pirfenidone |
| NCT02763969 Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis | Psoriasis | P1 | Completed | 357 | RCT, Double-blind | BMS-986202, Placebo, Interferon alpha-2a recombinant, Famotidine, Ustekinumab |
| NCT04269356 Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants | Healthy Participants | P1 | Completed | 8 | Open-label | BMS-986256, Milk of magnesia |
| NCT05162222 A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants | Healthy Participants | P1 | Completed | 30 | RCT, Open-label | Danicamtiv, Itraconazole, Diltiazem |
| NCT00609999 Ph I Dasatinib + Erlotinib in Recurrent MG | Glioblastoma, Gliosarcoma | P1 | Completed | 47 | Open-label | Erlotinib and Dasatinib |
| NCT04200963 A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | Urothelial Carcinoma, Urothelial Carcinoma Bladder | P1 | Completed | 78 | Open-label | IK-175, IK-175 and nivolumab |
| NCT01471210 Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma | P1 | Completed | 124 | Open-label | Urelumab (BMS-663513) |
| NCT02227459 Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) | Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) | P1 | Completed | 25 | RCT, Open-label | ND-L02-s0201 Injection |
| NCT03831438 Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis | Scleroderma, Diffuse | P1 | Completed | 9 | Open-label | AVID200 |
| NCT00707590 Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes Mellitus | P1 | Terminated | 120 | RCT, Double-blind | BMS-767778 or Placebo |
| NCT01176474 Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Melanoma (Skin) | P1 | Completed | 73 | Open-label | NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab |
| NCT04649710 A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants | Healthy Participants | P1 | Withdrawn | — | RCT, Double-blind | BMS-986036 |
| NCT00162149 ATV/Ritonavir Nevirapine Interaction (USPAC) | HIV Infections | P1 | Completed | 46 | Open-label | Nevirapine, Nevirapine + Atazanavir/Ritonavir, Nevirapine + Atazanavir/Ritonavir, Atazanavir + Ritonavir |
| NCT04763226 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants | Healthy Participants | P1 | Completed | 46 | RCT, Double-blind | BMS-986308, Furosemide |
| NCT00646776 Drug Interaction Study | Antivirals/HIV | P1 | Completed | 85 | RCT, Open-label | Rifabutin, Rifabutin + Atazanavir + Ritonavir |
| NCT05127174 Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Myeloproliferative Neoplasm | P1 | Terminated | 12 | RCT, Open-label | Fedratinib Pill |
| NCT00000737 A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome | Cachexia, HIV Infections | P1 | Completed | 56 | Open-label | Dronabinol, Megestrol acetate |
| NCT01525212 Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients | Chronic Hepatitis C | P1 | Withdrawn | — | RCT, Double-blind | BMS-929075, BMS-929075, BMS-929075, BMS-929075, Placebo matching BMS-929075, Placebo matching BMS-929075 |
| NCT00726505 Renal Mechanism of Action/Splay vs. TmG | Diabetes, NOS | P1 | Terminated | 1 | RCT, Open-label | Dapagliflozin |
| NCT03335553 A Study of Experimental Medication BMS-986235 in Healthy Subjects | Mediators of Inflammation | P1 | Completed | 122 | RCT, Double-blind | BMS-986235 |
| NCT01830205 Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment | Hepatitis C | P1 | Completed | 58 | Open-label | Daclatasvir |
| NCT01775631 Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | B-Cell Malignancies | P1 | Completed | 47 | Open-label | Urelumab, Rituximab |
| NCT03044873 Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin | Autoimmune Diseases, Inflammatory Diseases | P1 | Completed | 20 | Open-label | BMS-986165, Rosuvastatin |
| NCT05546151 A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent | Healthy Participants | P1 | Completed | 24 | RCT, Double-blind | BMS-986322 |
| NCT00300027 Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies | Gastrointestinal Neoplasms | P1 | Terminated | 50 | Open-label | BMS-582664 |
| NCT00024284 Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors | Unspecified Childhood Solid Tumor, Protocol Specific | P1 | Completed | — | — | carboplatin, irinotecan hydrochloride |
| NCT03667716 COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | Advanced Cancer, Ovarian Cancer | P1 | Completed | 121 | Open-label | COM701, COM701 with Opdivo (Nivolumab). |
| NCT01998126 Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | P1 | Completed | 14 | Open-label | Ipilimumab, Erlotinib, Crizotinib, Nivolumab |
| NCT02101125 Drug Interaction Study With Rosuvastatin | Immunosuppression For Disease | P1 | Completed | 26 | Open-label | BMS-986020, Rosuvastatin |
| NCT03422094 Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Glioblastoma | P1 | Terminated | 3 | Open-label | NeoVax, Nivolumab, Ipilimumab |
| NCT02902679 A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment | Thrombosis, Factor XI | P1 | Completed | 6 | Open-label | BMS-986177 |
| NCT00940524 Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | Leukemia, Acute Lymphoblastic Leukemia | P1 | Completed | 7 | Open-label | Dasatinib, Mitoxantrone, Cytarabine |
| NCT01838200 Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | Metastatic Melanoma | P1 | Terminated | 5 | Open-label | Bacillus Calmette-Guérin (BCG) vaccine, Ipilimumab, Isoniazid |
| NCT04448964 A Study of JNJ-70033093 in Healthy Participants | Healthy | P1 | Completed | 24 | RCT, Open-label | JNJ-70033093 |
| NCT02534636 Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis | Healthy Subjects | P1 | Completed | 140 | RCT, Double-blind | BMS-986165, Interferon alpha-2a recombinant, Famotidine |
| NCT02211469 A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects | Rheumatoid Arthritis | P1 | Completed | 41 | RCT, Double-blind | BMS-986104, Placebo |
| NCT00162097 Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment | HIV Infections, Hepatic Impairment | P1 | Completed | 21 | Open-label | efavirenz containing antiretroviral regimen, efavirenz containing antiretroviral regimen, efavirenz containing antiretroviral regimen, efavirenz containing antiretroviral regimen |
| NCT01455103 Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma | Stage III or IV Melanoma | P1 | Withdrawn | — | RCT, Open-label | BMS-936559 (Anti-PD-L1), BMS-936559 (Anti-PD-L1), BMS-936559 (Anti-PD-L1) |
| NCT05932303 A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants | Healthy Participants | P1 | Completed | 47 | Open-label | BMS-986278, Itraconazole, Gemfibrozil, Carbamazepine |
| NCT06211179 A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants | Healthy Volunteers | P1 | Completed | 34 | RCT, Open-label | Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT) |
| NCT01123824 Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects | Healthy | P1 | Completed | 40 | RCT, Double-blind | CLOPIDOGREL, placebo |
| NCT05678283 A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Withdrawn | — | Open-label | [14C]CC-90010, CC-90010 |
| NCT02323594 A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir | Hepatitis C Infection | P1 | Completed | 88 | RCT, Open-label | Daclatasvir, Daclatasvir, Asunaprevir, Daclatasvir |
| NCT01082562 Safety Study of BMS-844421 for Treatment of Hypercholesterolemia | Atherosclerosis, Hypercholesterolemia | P1 | Terminated | 40 | RCT, Double-blind | BMS-844421, 0.9% sodium chloride injection solution |
| NCT05932277 A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants | Healthy Volunteers | P1 | Completed | 22 | Open-label | BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine |
| NCT02982707 Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants | Thrombosis | P1 | Completed | 26 | Open-label | BMS-986177 |
| NCT02922452 A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects | Ischemic Stroke | P1 | Completed | 16 | Open-label | BMS-986141, Dilitazem |
| NCT01404572 Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects | HIV | P1 | Completed | 12 | RCT, Double-blind | Atazanavir (current formulation), Atazanavir, powder for oral use 1 (POU1), Atazanavir (POU2) |
| NCT02017730 To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers | Immunology | P1 | Completed | 20 | Open-label | BMS-986020, [11C]BMT-136088 |
| NCT00452673 Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | Advanced Breast Cancer | P1 | Completed | 52 | Open-label | Dasatinib, Capecitabine |
| NCT04086719 An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. | Healthy Male Volunteers | P1 | Completed | 16 | Open-label | BMS-986165, Pyrimethamine |
| NCT03507699 Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer | Colorectal Neoplasms Malignant, Liver Metastases | P1 | Completed | 19 | Open-label | Nivolumab Injection [Opdivo], Ipilimumab Injection [Yervoy], CMP-001 |
| NCT00277199 Comparability DE vs CD-CHO1 | Healthy Subjects | P1 | Completed | 30 | RCT, Open-label | Abatacept |
| NCT06568458 A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants | Healthy Participants | P1 | Completed | 71 | Open-label | Nintedanib, BMS 986278 |
| NCT02074358 A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects | Anticoagulation | P1 | Completed | 43 | RCT, Open-label | Apixaban, Cofact (4-Factor PCC), Beriplex P/N (4-Factor PCC), Placebo (Saline solution) |
| NCT04956627 A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants | Healthy Participants | P1 | Completed | 15 | RCT, Open-label | BMS-986166, Itraconazole, Extended Phenytoin Sodium, Gemfibrozil |
| NCT00000686 A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT | HIV Infections | P1 | Terminated | 35 | Open-label | Stavudine |
| NCT02536469 HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | Solid Tumor | P1 | Completed | 15 | Open-label | HuMax-IL8 |
| NCT04949269 A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants | Healthy Participants | P1 | Completed | 61 | RCT, Open-label | Deucravacitinib, Famotidine |
| NCT01836705 Effect of SAR302503 on ECG Activity in Patients With Solid Tumors | Neoplasm Malignant | P1 | Completed | 60 | Open-label | SAR302503 (TG101348), Placebo SAR302503, Panolosetron |
| NCT00859053 Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment | Hepatic Insufficiency | P1 | Completed | 46 | Open-label | BMS-790052 |
| NCT00554450 Renal Impairment in Type 2 Diabetic Subjects | Diabetes Mellitus, Type 2 | P1 | Completed | 40 | Open-label | Dapagliflozin |
| NCT03312426 An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants | Healthy Volunteers | P1 | Completed | 32 | RCT, Open-label | BMS-986205 |
| NCT01363817 Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma | P1 | Completed | 31 | Open-label | BMS-906024, Dexamethasone |
| NCT04634149 A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment | Moderate Liver Impairment, Severe Liver Impairment | P1 | Completed | 16 | Open-label | BMS-986036 |
| NCT01292655 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Cancer | P1 | Completed | 94 | Open-label | BMS-906024 |
| NCT03198013 A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males | Immunoscience | P1 | Completed | 120 | RCT, Double-blind | Prednisolone, BMS-791826, Placebo |
| NCT02600455 Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL | Rheumatoid Arthritis | Completed | 505 | — | Orencia | |
| NCT05742867 A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder | Urinary Bladder Neoplasms | Completed | 115 | — | — | |
| NCT03157674 Real-World Evidence and Treatment Patterns: Head and Neck Cancer | Head & Neck Cancer | Completed | 43,994 | — | — | |
| NCT03161145 A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread | Renal Cell Carcinoma | Completed | 297 | — | — | |
| NCT02758769 Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings | Rheumatoid Arthritis | Completed | 303 | — | ORENCIA Subcutaneous Injection | |
| NCT04043975 A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | Advanced or Metastatic Renal Cell Carcinoma | Completed | 286 | — | — | |
| NCT02600468 Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg | Rheumatoid Arthritis | Completed | 671 | — | Orencia | |
| NCT03466814 Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin | Undifferentiated Arthritis | Completed | 82 | — | — | |
| NCT02717364 Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma | Melanoma | Completed | 556 | — | — | |
| NCT07169708 A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) | Non Small Cell Lung Cancer NSCLC | Not Yet Recruiting | 100 | — | — | |
| NCT03165422 A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan | Melanoma | Completed | 68 | — | — | |
| NCT03273790 A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan | Non-Small Cell Lung Cancer | Completed | 939 | — | — | |
| NCT01386359 Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant | Kidney Transplantation | Completed | 914 | — | No Intervention | |
| NCT02974829 REALM China Extension Study | Hepatitis B, Chronic | Unknown | 4,000 | — | — | |
| NCT02666209 Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | Multiple Myeloma in Relapse, Multiple Myeloma | NO_LONGER_AVAILABLE | — | — | Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone | |
| NCT05539976 A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants | Healthy Participants | Completed | 10 | — | — | |
| NCT01192659 Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Completed | 16,492 | — | — | |
| NCT06851065 A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States | Myelodysplastic Syndromes | Completed | 418 | — | Luspatercept, Erythropoiesis-stimulating agents | |
| NCT04818151 Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data | Venous Thromboembolic Disease, Kidney Failure, Chronic | Completed | 14,914 | — | Warfarin, Apixaban | |
| NCT00002057 Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC | Candidiasis, Oral, HIV Infections | N/A | Completed | — | — | Nystatin |
| NCT03200977 Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab | Lymphoma | Completed | 95 | — | — | |
| NCT02447341 Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study) | Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke | Completed | 987 | — | — | |
| NCT05170685 Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab | NO_LONGER_AVAILABLE | — | — | Nivolumab plus Relatlimab FDC | ||
| NCT03114163 Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy | Head and Neck Cancer | Completed | 485 | — | — | |
| NCT02910999 Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy | Non-Small Cell Lung Cancer | Completed | 868 | — | — | |
| NCT07141563 A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC | Non-small Cell Lung Cancer (NSCLC) | Completed | 70 | — | Nivolumab + platinum-based chemotherapy | |
| NCT07434960 Expanded Access for Iberdomide | AVAILABLE | — | — | Iberdomide | ||
| NCT03812562 Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | Hepatocellular Carcinoma | Early P1 | Terminated | 2 | Open-label | Nivolumab |
| NCT05217082 A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure | Multiple Myeloma | Completed | 35 | — | — | |
| NCT01076738 Screening DIVA - Diffuse Vascular Disease | Peripheral Vascular Diseases | Completed | 2,233 | — | — | |
| NCT03568435 Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants | Kidney Cancer, Renal Cancer | Completed | 212 | — | — | |
| NCT02975115 Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization | Chronic Myelocytic Leukemia | Unknown | 102 | — | — | |
| NCT02794636 Interferon Toxicities in Melanoma Treatment | Stage III Melanoma | Completed | 436 | — | — | |
| NCT00312598 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine | Schizophrenia, Schizoaffective Disorder | Completed | 30 | — | Aripiprazole | |
| NCT00992420 Genotype Information and Functional Testing Study | Coronary Artery Disease | Completed | 2,000 | — | — | |
| NCT03521908 A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot | Venous Thromboembolism (VTE) | Completed | 35,756 | — | — | |
| NCT06994117 Expanded Access for Mezigdomide | AVAILABLE | — | — | Mezigdomide | ||
| NCT05218902 A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Completed | 290 | — | — | |
| NCT00149591 The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial) | Myocardial Infarction, Coronary Artery Disease | N/A | Unknown | 300 | RCT, Open-label | — |
| NCT01685918 Safety and Effectiveness of Biological DMARDs in Elderly Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Unknown | 600 | — | — | |
| NCT02921126 Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy | Anticoagulation | Completed | 9,914 | — | — | |
| NCT00716352 Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes | Acute Coronary Syndromes, Coronary Artery Disease | N/A | Completed | 1,340 | RCT | — |
| NCT00002274 A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine | HIV Infections, Leukoencephalopathy, Progressive Multifocal | N/A | Completed | — | Open-label | Didanosine |
| NCT02475382 Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen | Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer | NO_LONGER_AVAILABLE | — | — | Nivolumab | |
| NCT03696173 Safety Study of Abatacept in Rheumatoid Arthritis Participants | Rheumatoid Arthritis | Completed | 5,800 | — | — | |
| NCT01176656 Hypoglycemia: Physician and Patient Perspectives | Type 2 Diabetes Mellitus, Hypoglycemia | Completed | 800 | — | — | |
| NCT05432622 A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy | Melanoma | Completed | 95 | — | — | |
| NCT01196273 Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up | Coronary Heart Disease, Heart Failure | Completed | 1,424 | — | — | |
| NCT00430027 Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | N/A | Terminated | 8 | Open-label | Capecitabine, Oxaliplatin, Cetuximab |
| NCT02113657 T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | Early P1 | Completed | 30 | Open-label | Ipilimumab |
| NCT02098616 Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus | Hepatitis C | N/A | Completed | 25 | Open-label | DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV |
| NCT05621148 REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy | CLL, Relapsed, CLL, Refractory | Completed | 152 | — | — | |
| NCT02856646 Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices | Hodgkin's Disease | Completed | 290 | — | — | |
| NCT02833233 A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | Breast Cancer | N/A | Completed | 5 | Open-label | Ipilimumab, Nivolumab |
| NCT07168655 Mavacamten in Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | 163 | — | Mavacamten | |
| NCT06565975 Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France | Acute Myeloid Leukemia (AML) | Completed | 112 | — | Oral azacitidine | |
| NCT05308966 Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) | Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm | Completed | 204 | — | — | |
| NCT00169949 Aripiprazole Treatment of the Prodrome | Prodromal Schizophrenia, Prodromal Psychosis | N/A | Terminated | 30 | Open-label | aripiprazole |
| NCT00226317 Aripiprazole in the Treatment of Bipolar Depression | Bipolar Disorder | N/A | Completed | 20 | Open-label | Aripiprazole |
| NCT03002740 Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation | Non-valvular Atrial Fibrillation | Withdrawn | — | — | — | |
| NCT01337479 A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials | Hepatitis B | Completed | 1,097 | — | — | |
| NCT02346942 Factors Associated With Biologic DMARD Switching | Rheumatoid Arthritis | Completed | 4,099 | — | — | |
| NCT02334852 Registry of Atrial Fibrillation and Embolic Risk in Mexico | Atrial Fibrillation | Completed | 1,200 | — | — | |
| NCT02990611 Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy | Melanoma | Completed | 1,087 | — | — | |
| NCT02514304 Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding | Gastrointestinal Hemorrhage, Cardiovascular Diseases | Completed | 4,745 | — | — | |
| NCT05335031 A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) | Multiple Sclerosis, Relapsing-Remitting | Completed | 450 | — | Ozanimod | |
| NCT06338202 Real-World Effectiveness of Mavacamten in Canada | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | 115 | — | Mavacamten | |
| NCT04256213 COL Immunotherapy Before Radiochimio + Ipilimumab | Cervix Cancer | N/A | Completed | 40 | Open-label | Nivolumab and Ipilimumab |
| NCT03059888 Trial of Orencia in Patients With Myasthenia Gravis | Myasthenia Gravis | Early P1 | Terminated | 6 | Open-label | Abatacept Injection |
| NCT01293279 HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China | Hepatitis C | Completed | 997 | — | — | |
| NCT03843619 Electronic and Lab Pre-screening of New Rheumatology Patients With Rheumatoid Arthritis | Rheumatoid Arthritis, Inflammatory Arthritis | Unknown | 200 | — | — | |
| NCT05658601 A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Completed | 104 | — | — | |
| NCT01565863 Progressive Goal Attainment Program for Veterans | Mental Disorders, Worries; Pain or Disability | N/A | Completed | 199 | RCT, Open-label | — |
| NCT01088321 Safety Study of Abatacept to Treat Rheumatoid Arthritis (A) | Rheumatoid Arthritis | Completed | 81,332 | — | — | |
| NCT02754154 Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants | Atrial Fibrillation | Completed | 321,182 | — | Warfarin, Apixaban, Dabigatran, Rivaroxaban | |
| NCT05517837 A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants | Healthy Participants | Early P1 | Terminated | 46 | RCT, Double-blind | BMS-986421 |
| NCT00000969 A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy | HIV Infections | N/A | Completed | 400 | — | Zalcitabine, Didanosine |
| NCT03515083 Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm | Non-valvular Atrial Fibrillation | N/A | Completed | 100 | RCT, Open-label | — |
| NCT02598466 Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa | Rheumatoid Arthritis | Completed | 69 | — | Abatacept | |
| NCT01275794 Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage | Type 2 Diabetes | Completed | 1,849 | — | — | |
| NCT02769078 Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S | Atrial Fibrillation | Completed | 14,201 | — | dabigatran, rivaroxaban, apixaban, warfarin | |
| NCT01476943 Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study | Transplantation, Organ | Completed | 72,392 | — | — | |
| NCT01701674 Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Metastatic Melanoma | N/A | Completed | 13 | Open-label | Ipilimumab, Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL |